Rate of progression of cognitive decline in Alzheimer's disease: Effect of butyrylcholinesterase K gene variation

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 5, 2005, Pages 640-643

  Holmes, C ^a   Ballard, C ^b   Lehmann, D ^c   Smith, A David ^c   Beaumont, H ^c   Day, I N ^a   Khan, M Nadeem ^d   Lovestone, S ^d   McCulley, M ^a   Morris, C M ^b   Munoz, D G ^e,f   O'Brien, K ^b   Russ, C ^d   Del Ser, T ^e,f   Warden, D ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Institute of Psychiatry ^*  (Spain)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; COGNITION DISORDERS; COHORT STUDIES; DEMOGRAPHY; FEMALE; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; VARIATION (GENETICS);

EID: 20244371673     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.039321     Document Type: Article

References (22)

1. Perrault A, Wolfson C, Egan M, et al. Prognostic factors for functional independence in older adults with mild dementia: results from the Canadian study of health and aging. Alzheimer Dis Assoc Disord 2002;16:42-7.
2. Holmes C, Lovestone S. Long term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 2003;32:200-4.
3. Corey BJ. The natural history of Alzheimer's disease. Dementia 2000;34:405-15.
4. Holmes C. Genotype and phenotype in Alzheimer's disease. Br J Psychiatry 2002;180:131-4.
5. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, ed. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000.
6. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-7.
7. Geula C, Mesulam MM. Cholinesterases and pathology of Alzheimer's disease. Alzheimer Dis Assoc Disord 1995;9:23-8.
8. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992;50:1086-103.
9. Perry E, McKeith I, Ballard C. The K variant of the butyrylcholinesterase enzyme is associated with significantly slower cognitive decline and predicts treatment response in dementia patients. Neurology 2003;10:1852-3.
10. Lehmann DJ, Williams J, McBroom J, et al. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001;108:541-4.
11. Holmes C. The Camberwell dementia case register. InI J Geriatr Psychiatry 1996;11:369-75.
12. McKhann G, Drachmen D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
13. Holmes C, Cairns N, Lantos P, et al. The validity of current research diagnostic criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45-50.
14. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-98.
15. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992;340:1179-83.
16. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
17. Nagy Z, Esiri M, Hindley NJ, et al. Accuracy of clinical criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Disord 1998;9:219-26.
18. Jensen FS, Nielsen LR, Schwartz M. Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Hered 1996;46:26-31.
19. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-9.
20. Burns A, Lewis G, Jacoby R, et al. Factors affecting survival in Alzheimer's disease. Psychol Med 1991;21:303-70.
21. Clark-CM, Sheppard L, Fillenbaum G, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the consortium to establish a registry for Alzheimer's disease. Arch Neurol 1999;56:857-62.
22. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-7.